bromodeoxyuridine has been researched along with Hypertrophy, Right Ventricular in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bloch, KD; Brouckaert, P; Buys, E; Collen, D; Dewerchin, M; Gillijns, H; Graveline, A; Ichinose, F; Janssens, S; Marsboom, G; Pellens, M; Pokreisz, P; Sips, P; Swinnen, M; Vermeersch, P | 1 |
1 other study(ies) available for bromodeoxyuridine and Hypertrophy, Right Ventricular
Article | Year |
---|---|
Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Topics: Acute Disease; Animals; Antimetabolites; Blood Pressure; Bromodeoxyuridine; Chronic Disease; Cyclic GMP; Dimerization; Female; Guanylate Cyclase; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Mice; Mice, Mutant Strains; Nitric Oxide; Pulmonary Artery; Pulmonary Circulation; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Vasodilation; Ventricular Function, Right | 2007 |